Skip to main content
Figure 3 | Journal of Ovarian Research

Figure 3

From: Sequential combination therapy with flavopiridol and autocatalytic caspase-3 driven by amplified hTERT promoter synergistically suppresses human ovarian carcinoma growth in vitro and in mice

Figure 3

Flow cytometric analysis in OVCAR3 cells. A-D: Cells were treated with AdHTVP2G5-rev-casp3(MOI = 10), 36 h later, followed by DMSO or 300 nM flavopiridol for 48 hs. E-H, After treatment with AdHTVP2G5-rev-casp3(MOI = 10), 72 h later, cells were accumulated in S-phase. And then cells were subsequently treated with DMSO or 300 nM flavopiridol for 48 hs. Treatment with flavopiridol after recruitment to S-phase results in death of the majority of the cell population, inferred from the large percentage of cells with sub-G1 DNA content.

Back to article page